On January 21, 2022 Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, reported that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Friday, January 28, 2022 at 11:00 a.m. ET (Press release, Geron, JAN 21, 2022, View Source [SID1234606688]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

On January 21, 2022 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference (Press release, Karyopharm, JAN 21, 2022, View Source [SID1234606687]). The conference is being conducted in a virtual format and the presentation will take place on Friday, January 28 at 9:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company’s website, View Source, and will be available for replay for 30 days following the event.

On January 21, 2022 GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and chronic liver diseases, reported the half-year report of the liquidity contract with Crédit Industriel et Commercial (Press release, Genfit, JAN 21, 2022, https://ir.genfit.com/news-releases/news-release-details/genfit-half-year-report-liquidity-contract-credit-industriel-3 [SID1234606684]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2021:

137,012 shares
€512 873.86
During the second half of 2021, total trading was:

On the buy side: 469,086 shares for a total amount of €1,824,630.43
On the sell side: 437,124 shares for a total amount of €1,690,993.82
During this same period, the number of trades were:

On the buy side: 1,402
On the sell side: 1,389
As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

27, 911 shares
€769 849,43

On January 21, 2022 ArcticZymes Technologies reported that fourth quarter and the full year 2021 on Thursday, 27 January 2022 at 08.30 a.m (Press release, Biotec Pharmacon, JAN 21, 2022, View Source [SID1234606683]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will host an online presentation for investors, analysts, and media at 08:30 a.m. on Thursday, 27 January 2022, which will be followed by a Q&A session.

CEO, Jethro Holter and CFO, Børge Sørvoll will hold the presentation.

Participants who want to participate in the live webcast are asked to send an email to [email protected] for a separate invitation, which will be distributed 1 day prior to the meeting. Participants who want to participate by telephone should dial in on +47 21 40 24 87 with conference id: 141 573 333#. It will be possible to post questions through the webcast and over the phone after the presentation is finished.

The report for the fourth quarter and the full year 2021 will be available on www.newsweb.no and on the company’s homepage www.arcticzymes.com from 07.00 a.m. on Thursday, 27 January 2022.

On January 20, 2022 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, reported it will host a conference call and webcast to provide a clinical update on Wednesday, January 26, 2022 at 4:30 p.m. EST (Press release, Cue Biopharma, JAN 20, 2022, View Source [SID1234608265]). Live and archived versions of the event can be accessed via the Company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of the Cue Biopharma executive management team will provide an update from the Company’s ongoing clinical trials with CUE-101, its lead and representative IL-2 based drug product candidate from the CUE-100 series. CUE-101 is currently in a Phase 1b clinical trial for the treatment of HPV+ recurrent/metastatic head and neck squamous cell carcinoma. The discussion will focus on recent data updates from the Phase 1b monotherapy dose expansion trial and the dose escalation combination trial evaluating CUE-101 front line with Merck’s KEYTRUDA (pembrolizumab). Management will also provide an update on the Company’s pipeline development progress from the IL-2 based CUE-100 series including CUE-102, with an Investigational New Drug (IND) filing planned for the first quarter of 2022, as well as updates on its strategic objectives and anticipated milestones.

Webcast Details

Wednesday, January 26, 2022 at 4:30 p.m. EST
Investors: 877-407-9208
International: 201-493-6784
Conference ID: 13726509
Webcast: View Source;tp_key=7a7d92f501